A

Amgen

Makes biotech medicines for serious illnesses

Principal Engineer - Electrical

Full-Time
$140.3k - $189.9k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Senior, Expert
Bachelor's, Master's, PhD, Associate's
New Albany, OH, USA
In PersonBased onsite in New Albany, Ohio; occasional support outside normal business hours may be required.
Electrical EngineeringPower Systems Engineering
H1B Sponsorship Available

About the job

Requirements
  • Doctorate degree and 2 years of engineering experience; or a master’s degree and 4 years of engineering experience; or a bachelor’s degree and 6 years of engineering experience; or an associate’s degree and 10 years of engineering experience; or a high school diploma/GED and 12 years of engineering experience.
  • A bachelor’s degree in Electrical Engineering is required.
  • 10+ years of progressively responsible electrical engineering experience supporting complex industrial, manufacturing, pharmaceutical, biotechnology, utility, or other mission-critical facilities.
  • Demonstrated technical leadership in medium- and low-voltage power distribution, including substations, switchgear, transformers, generators, automatic transfer switches, paralleling gear, UPS systems, and protective relaying.
  • Experience leading electrical reliability initiatives, electrical-system troubleshooting, root-cause investigations, and corrective actions following equipment failures, power-quality events, or utility interruptions.
  • Experience developing electrical system studies and strategies, including short-circuit, coordination, arc-flash, load-flow, harmonics, and power-quality assessments.
  • Proven experience leading electrical capital projects from early scope development and design through installation, commissioning, and operational turnover.
  • Strong working knowledge of NFPA 70, NFPA 70E, NEC, OSHA requirements, IEEE standards, and electrical safety practices.
  • Ability to translate complex electrical risks and technical recommendations into clear decisions for operations and site leadership.
  • Demonstrated ability to influence cross-functional teams, mentor technical staff, and manage external engineering firms, contractors, and equipment vendors.
Responsibilities
  • Provide technical leadership for site electrical infrastructure, including medium-voltage distribution, substations, switchgear, transformers, generators, ATS/paralleling systems, UPS systems, and low-voltage distribution.
  • Serve as the subject matter expert for electrical reliability, power quality, emergency power, system protection, and electrical safety.
  • Lead complex troubleshooting and root-cause investigations involving electrical failures, voltage disturbances, protection-system operation, generator and transfer system events, and facility outages.
  • Develop and maintain electrical system standards, operating procedures, failure-mode analyses, preventive maintenance strategies, and critical-spares recommendations.
  • Support the planning, design, execution, commissioning, and turnover of capital projects, facility improvements, equipment installations, and expansion activities.
  • Review electrical designs, specifications, studies, and contractor work to ensure compliance with applicable codes, company standards, GMP expectations, and site reliability requirements.
  • Lead or support arc-flash, coordination, short-circuit, load-flow, harmonics, and power-quality studies, translating results into practical site improvements.
  • Partner with Operations and Maintenance teams to improve equipment reliability, reduce operational risk, and minimize manufacturing downtime.
  • Provide technical oversight of electrical contractors, engineering firms, equipment vendors, and service providers.
  • Support electrical safety programs, including NFPA 70E compliance, energized-work practices, lockout/tagout considerations, and incident prevention.
  • Participate in site shutdown planning, outage coordination, emergency-response planning, and return-to-service activities.
  • Mentor engineers and technical staff while strengthening electrical engineering capability across the site.
  • Communicate technical risks, reliability priorities, project status, and investment needs clearly to site leadership.
  • Support the Facilities & Engineering operations team and ensure the safe, reliable, compliant, and efficient operation of site utility, facility, and infrastructure electrical systems supporting commercial manufacturing operations.
Desired Qualifications
  • A master’s degree in Electrical Engineering is preferred.
  • A Professional Engineer (PE) license is preferred.
  • Experience working in a regulated GMP, life-sciences, food, semiconductor, or similarly controlled manufacturing environment is strongly preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.